Phase 2a trial of ZPL-3893787 (ZPL-389), a histamine H4 receptor antagonist, for atopic dermatitis

Thomas Werfel, MD, from Hannover Medical School, Hannover, Germany, discusses the design and outcomes from a phase 2a proof-of-concept clinical trial evaluating ZPL-3893787 (ZPL-389), an oral histamine H4 receptor antagonist, for the treatment of moderate-to-severe atopic dermatitis in adults. The trial outcomes to date are presented at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2016, held from 11–15 June in Austria, Vienna.

This content is supported by Ziarco Pharma Ltd.

EAACI is an independent organisation and cannot, therefore, endorse medicines or products.

Year of Production:
Running Time:


Comments are closed.